The U.S. Food and Drug Administration (FDA) has updated the prescribing label for Lupkynis (voclosporin), which is approved to treat a severe manifestation of lupus called lupus nephritis, to include data that shows it continues to safely preserve kidney function for up to three years. The data came…
A CAR T-cell therapy targeting B-cells, a type of immune cells, was found to clear disease-causing autoantibodies from the bloodstream of eight people with systemic lupus erythematosus (SLE) — without compromising the patients’ ability to respond to vaccines — new trial data show. The experimental therapy also drove the…
GlaxoSmithKline (GSK) is recruiting participants for a Phase 3 clinical trial to evaluate the effectiveness and safety of Benlysta (belimumab) in combination with rituximab for treating patients with active systemic lupus erythematosus (SLE). The study will evaluate if the treatment combo is better at sustaining low disease activity or remission than Benlysta…
Adding Rituxan (rituximab) to maintenance therapy with immunosuppressants and corticosteroids may help patients control their systemic lupus erythematosus (SLE), a new Japanese study suggests. The study, “Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus,” conducted in a small group of Japanese patients,…